Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

Tipranks - Tipranks - Fri Feb 13, 7:14AM CST

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Royalty Pharma, with a price target of $54.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Gerberry is a 5-star analyst with an average return of 16.7% and a 61.22% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Bristol-Myers Squibb.

In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $50.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Royalty Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $609.29 million and a net profit of $288.22 million. In comparison, last year the company earned a revenue of $564.69 million and had a net profit of $543.99 million

Read More on RPRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).